Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Ascendis Pharma A/SASND · Entity 1628 | Director | September 02, 2026 | September 03, 2026 |
| Evaxion A/SEVAX · Entity 7553 | Director | March 18, 2026 | March 19, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Ascendis Pharma A/S
Report date September 02, 2026 · Filed September 03, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Ordinary SharesSEC Table I · non-derivative | Direct | 4,000 |
Reported balance
After 2026-09-02 transaction · row 1
1 source rowRow 1 · 2026-09-02 · Sale · Disposed 236 · Balance 4,000 |
Evaxion A/S
Report date March 18, 2026 · Filed March 19, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Ordinary SharesSEC Table I · non-derivative | IndirectBy LH2022 ApS | 258,029 |
Reported balance
Holding disclosure · report date 2026-03-18 · row 1
Holding and transaction disclosures are not merged.
1 source rowRow 1 · Balance 258,029 F1: Mr. Holtug is a control person of such entity. |
| WarrantsSEC Table II · derivative / convertible security · Conversion / exercise price $0.74 · Expires 2026-12-21 | IndirectBy LH2022 ApS | Not disclosed |
Reported balance
Holding disclosure · report date 2026-03-18 · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · Balance Not disclosed F2: Warrants pursuant to private placement that closed 12/21/2023. F1: Mr. Holtug is a control person of such entity. |
| WarrantsSEC Table II · derivative / convertible security · Conversion / exercise price $0.06 · Expires 2030-01-31 | IndirectBy LH2022 ApS | Not disclosed |
Reported balance
Holding disclosure · report date 2026-03-18 · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · Balance Not disclosed F3: Warrants pursuant to public offering that closed 1/31/2025. F1: Mr. Holtug is a control person of such entity. |
| WarrantsSEC Table II · derivative / convertible security · Conversion / exercise price $5.38 · Expires 2031-12-31 | Direct | Not disclosed |
Reported balance
Holding disclosure · report date 2026-03-18 · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · Balance Not disclosed |
| WarrantsSEC Table II · derivative / convertible security · Conversion / exercise price $2.23 · Expires 2031-12-31 | Direct | Not disclosed |
Reported balance
Holding disclosure · report date 2026-03-18 · row 5
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 5 · Balance Not disclosed F4: Vesting is 1/12 per month over 12 months from the initial exercise date indicated. |
| WarrantsSEC Table II · derivative / convertible security · Conversion / exercise price $0.75 · Expires 2031-12-31 | Direct | Not disclosed |
Reported balance
Holding disclosure · report date 2026-03-18 · row 6
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 6 · Balance Not disclosed F4: Vesting is 1/12 per month over 12 months from the initial exercise date indicated. |
| WarrantsSEC Table II · derivative / convertible security · Conversion / exercise price $0.40 · Expires 2031-12-31 | Direct | Not disclosed |
Reported balance
Holding disclosure · report date 2026-03-18 · row 7
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 7 · Balance Not disclosed F4: Vesting is 1/12 per month over 12 months from the initial exercise date indicated. |
| WarrantsSEC Table II · derivative / convertible security · Conversion / exercise price $0.07 · Expires 2031-12-31 | Direct | Not disclosed |
Reported balance
Holding disclosure · report date 2026-03-18 · row 8
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 8 · Balance Not disclosed F4: Vesting is 1/12 per month over 12 months from the initial exercise date indicated. |
Filing footnotes · ownership attribution and instrument terms
F1: Mr. Holtug is a control person of such entity.
F2: Warrants pursuant to private placement that closed 12/21/2023.
F3: Warrants pursuant to public offering that closed 1/31/2025.
F4: Vesting is 1/12 per month over 12 months from the initial exercise date indicated.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| September 02, 2026 Filed Sep 3, 2026 20:09 UTC | Ascendis Pharma A/S ASND · Entity 1628 | SaleOrdinary Shares | 236 | $264.13 | $62,334.59 |
DisclosureSEC source: 0001610717-26-000395 · form4.xml · nonDerivative · entry 1 HOLTUG LARS · CIK 0001965626 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 4,000 Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.